Gilead price target raised to $175 from $155 at UBS

UBS raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps a Buy rating on the shares. Gilead will present Phase I Q6M pharmacokinetic data for long-acting integrase inhibitors in HIV treatment at CROI, marking a key step in advancing its next wave of six-month dosing therapies, the analyst tells investors in a research note. If successful, these agents could transition patients from daily Biktarvy to long-acting regimens, helping sustain leadership in the $15B HIV treatment market and extend revenue durability beyond Biktarvy’s 2036 patent protection, the firm says.